{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T08:28:40Z","timestamp":1794385720298,"version":"4.9.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion Medicine Reviews"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1016\/j.tmrv.2010.11.005","type":"journal-article","created":{"date-parts":[[2011,2,24]],"date-time":"2011-02-24T14:18:35Z","timestamp":1298557115000},"page":"133-144","source":"Crossref","is-referenced-by-count":9,"title":["Universal White Blood Cell Reduction in Europe: Has Transmission of Variant Creutzfeldt-Jakob Disease Been Prevented?"],"prefix":"10.1016","volume":"25","author":[{"given":"Eleftherios C.","family":"Vamvakas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tmrv.2010.11.005_bb0005","first-page":"542","article-title":"Prion and the blood immune systems","volume":"90","author":"Mabbott","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0010","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1046\/j.1537-2995.2001.41050691.x","article-title":"Universal white-cell reduction: The case for and against","volume":"41","author":"Vamvakas","year":"2001","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0887-7963(00)80114-5","article-title":"Leukocyte reduction of blood components: Public policy and new technology","volume":"14","author":"Dzik","year":"2000","journal-title":"Transf Med Rev"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0020","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1097\/01.ta.0000199537.09201.7b","article-title":"The clinical benefits of leukoreduction of blood products","volume":"60","author":"Blajchman","year":"2006","journal-title":"J Trauma"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0025","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1046\/j.1537-2995.1997.37297203512.x","article-title":"Allogeneic blood transfusions, immunomodulation and postoperative bacterial infection. Do we have the answers yet?","volume":"37","author":"Blajchman","year":"1997","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0030","series-title":"Immunomodulatory Effects of Blood Transfusion","year":"1999"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0035","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.blre.2007.07.003","article-title":"Transfusion-related immunomodulation: An update","volume":"21","author":"Vamvakas","year":"2007","journal-title":"Blood Rev"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0040","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1126\/science.288.5468.979","article-title":"Risk management: Science and the precautionary principle","volume":"288","author":"Foster","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0045","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1053\/tmrv.2003.50007","article-title":"The application of the precautionary principle to the blood system: The Canadian blood system's vCJD donor deferral policy","volume":"17","author":"Wilson","year":"2003","journal-title":"Transf Med Rev"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0050","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1111\/j.1537-2995.2004.04116.x","article-title":"The success of precaution? Managing the risk of transfusion transmission of variant Creutzfeldt-Jakob disease","volume":"47","author":"Wilson","year":"2004","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0055","author":"University of Edinburgh"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0060","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2334-3-4","article-title":"Updated projections of future vCJD deaths in the UK","volume":"3","author":"Ghani","year":"2003","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0065","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/path.1580","article-title":"Prevalence of lymphoreticular prion protein accumulation in UK tissue samples","volume":"203","author":"Hilton","year":"2004","journal-title":"J Pathol"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0070","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1098\/rsif.2004.0017","article-title":"Projections of future course of the primary vCJD epidemic in the UK: inclusion of subclinical infection and the possibility of wider genetic susceptibility","volume":"2","author":"Clark","year":"2005","journal-title":"J R Soc Interface"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0075","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1126\/science.1103932","article-title":"Human prion protein with valine 129 prevents expression of variant CJD phenotype","volume":"306","author":"Wadsworth","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0080","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1016\/S0140-6736(06)68930-7","article-title":"Kuru in the 21st century\u2014an acquired human prion disease with very long incubation periods","volume":"367","author":"Collinge","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0085","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1098\/rsif.2007.0216","article-title":"Is there a potential for an epidemic of variant Creutzfeldt-Jakob disease via blood transfusion in the UK?","volume":"4","author":"Clarke","year":"2007","journal-title":"J R Soc Interface"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0090","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1474-4422(06)70413-6","article-title":"Predicting susceptibility and incubation time of human-to-human transmission of vCJD","volume":"5","author":"Bishop","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0095","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1136\/bmj.38804.511644.55","article-title":"Variant Creutzfeldt-Jakob disease: prion protein genotype analysis of positive appendix tissue samples from a retrospective prevalence study","volume":"332","author":"Ironside","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0100","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1001\/archneur.64.12.1780","article-title":"Creutzfeldt-Jakob disease, prion-protein gene codon 129 VV, and a novel PrPSc type in a young British woman","volume":"64","author":"Mead","year":"2007","journal-title":"Arch Neurol"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0105","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0140-6736(03)15247-6","article-title":"Patient's death from vCJD may be linked to blood transfusion. Committee to discuss need for further precautions to prevent possible vCJD transmission through blood","volume":"363","author":"Pincock","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0110","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0140-6736(04)15486-X","article-title":"Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion","volume":"363","author":"Llewelyn","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0115","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1423-0410.2006.00833.x","article-title":"Creutzfeldt-Jakob disease and blood transfusion: Results of the UK Transfusion Epidemiology Review Study","volume":"91","author":"Hewitt","year":"2006","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0120","article-title":"Fourth case of transfusion-associated variant CJD","volume":"1","author":"Health Protection Agency","year":"2007","journal-title":"Health Prot Rep"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0125","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1537-2995.2008.02044.x","article-title":"From cows to sensible blood transfusion: The risk of prion transmission from labile blood components in the United Kingdom and France","volume":"49","author":"Lefr\u00e8re","year":"2009","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0130","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/j.1537-2995.2010.02614.x","article-title":"Variant Creutzfeldt-Jacob disease in a transfusion recipient: Coincidence or cause?","volume":"50","author":"Cholan","year":"2010","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0135","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1128\/JVI.80.1.474-482.2006","article-title":"Resistance of neonatal mice to scrapie is associated with inefficient infection of the premature spleen","volume":"80","author":"Irena","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0140","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1055\/s-0037-1615387","article-title":"Retrospective neuropathological review of prion disease in UK hemophilia patients","volume":"80","author":"Lee","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0145","author":"Health Protection Agency"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0150","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1182\/blood-2008-04-152520","article-title":"Prion diseases are efficiently transmitted by blood transfusion in sheep","volume":"112","author":"Houston","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0155","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1365-2141.2008.07376.x","article-title":"An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products","volume":"144","author":"Turner","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0160","author":"SEAC"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0165","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1046\/j.1537-2995.1998.38998408999.x","article-title":"The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissiform spongiform encephalopathy","volume":"38","author":"Brown","year":"1998","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0170","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1046\/j.0041-1132.2003.00586.x","article-title":"Similar levels of infectivity in the blood of mice infected with human-derived vCJD and GSS strains of transmissible spongiform encephalopathy","volume":"43","author":"Cervenakova","year":"2003","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0175","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1016\/S0140-6736(06)69897-8","article-title":"Reduction in infectivity of endogenous transmissible spongiform encephalopathies present in blood by adsorption to selective affinity resins","volume":"368","author":"Gregori","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0180","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(04)16812-8","article-title":"Effectiveness of leukoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood","volume":"364","author":"Gregori","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0185","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1111\/j.1537-2995.2006.00865.x","article-title":"Reduction of transmissible spongiform encephalopathy infectivity from human red cells with prion protein affinity ligands","volume":"46","author":"Gregori","year":"2006","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0190","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1423-0410.2005.00703.x","article-title":"In-vitro evaluation of the Pall Leukotrap affinity prion reduction filter as a secondary device following primary leukoreduction","volume":"89","author":"Saunders","year":"2007","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0195","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1111\/j.1537-2995.2005.00640.x","article-title":"Removal of exogenous (spiked) and endogenous prion infectivity from red cells with a new prototype of leukocyte filtration filer","volume":"45","author":"Sowenimo-Coker","year":"2005","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0200","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1423-0410.2006.00765.x","article-title":"Pall leukotrap affinity prion-reduction filter removes exogenous infectious prions and endogenous infectivity from red cell concentrates","volume":"90","author":"Sowenimo-Coker","year":"2006","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0205","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/j.1537-2995.2009.02500.x","article-title":"Prion reduction of red blood cells: Impact on component quality","volume":"50","author":"Wiltshire","year":"2010","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0210","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1423-0410.2010.01330.x","article-title":"Phase I\/II safety study of transfusion of prion-filtered red-cell concentrates in transfusion-dependent patients","volume":"99","author":"Cahill","year":"2010","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0215","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1537-2995.2010.02638.x","article-title":"Prions and precautions: be careful for what you ask","volume":"50","author":"Dodd","year":"2010","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0220","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1111\/j.1537-2995.2005.00684.x","article-title":"Beyond leukodepletion: Removing infectious prions by filtration","volume":"45","author":"Eglin","year":"2005","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0225","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1423-0410.2005.00683.x","article-title":"Blood infectivity, processing, and screening tests in transmissible spongiform encephalopathy","volume":"89","author":"Brown","year":"2005","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0230","series-title":"The effect of leukodepletion on transmission of BSE by transfusion of sheep blood components. Prion 2009\u2014Transmissible Spongiform Encephalopathies Meeting, September 23-25","author":"Blanco","year":"2009"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0235","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1365-2141.2009.07840.x","article-title":"Transfusion-related acute lung injury (TRALI): A clinical review with emphasis on the critically ill","volume":"147","author":"Benson","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0240","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1128\/JVI.76.9.4649-4650.2002","article-title":"Scrapie infectivity in hamster blood is not associated with platelets","volume":"76","author":"Holada","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0245","series-title":"Position statement: Position statement on TSE infectivity in blood","author":"SEAC","year":"2006"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0250","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1046\/j.1365-2141.1999.01789.x","article-title":"Distribution of cell-associated prion protein in normal adult blood determined by flow cytometry","volume":"107","author":"Barclay","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0255","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1046\/j.1537-2995.2000.40060754.x","article-title":"Infectivity of buffy coat in variant CJD","volume":"40","author":"Sivakumaran","year":"2000","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0260","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.tmrv.2008.12.004","article-title":"Properties of pathogen-inactivated plasma components","volume":"23","author":"Prowse","year":"2009","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0265","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.beha.2005.01.033","article-title":"Risks and side-effects of therapy with plasma and plasma fractions","volume":"19","author":"MacLennan","year":"2006","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0270","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1423-0410.2005.00702.x","article-title":"Variant Creutzfeldt-Jakob disease transmission by plasma products: Assessing and communicating risk in an era of scientific uncertainty","volume":"89","author":"Farrugia","year":"2005","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2010.11.005_bb0275","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3201\/eid1301.060396","article-title":"Blood transfusion and spread of variant Creutzfeldt-Jacob disease","volume":"13","author":"Dietz","year":"2007","journal-title":"Emerg Infect Dis"}],"container-title":["Transfusion Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796310000866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796310000866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T20:18:33Z","timestamp":1560025113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887796310000866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S0887796310000866"],"URL":"https:\/\/doi.org\/10.1016\/j.tmrv.2010.11.005","relation":{},"ISSN":["0887-7963"],"issn-type":[{"value":"0887-7963","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}